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INTRODUCTION
Prostate cancer (PCa) is a common disease with incidence rates that rise dramatically with advancing age. Though clearly neoplastic, the vast majority of prostate cancers behave in an indolent fashion. Men with indolent disease are currently offered a treatment plan that involves deferred intervention or active surveillance (AS). However, two of the major limitations and concerns for AS strategies involve under-sampling of existing tumor foci (which represents a significant risk of under-grading the tumor) and requirements for invasive (biopsy) methods for cancer assessments. Thus, to this end, there is a significant clinical need for the development of biomarkers that can be measured noninvasively and can distinguish between men undergoing AS that develop high grade prostate cancer and men with indolent disease.
The Gleason scoring system is considered one of the most powerful prognosticators in PCa 1, 2 , thus this proposal will test the hypothesis that transcripts associated with high Gleason grade cancers are quantifiable in urine samples from men with prostate cancer, and that measurements of grade-associated transcripts will reflect the presence of higher-grade nonindolent tumors. We expect that a urine-based assay of GP-associated transcripts will identify occult higher grade cancers that either were missed on initial diagnostic biopsies or that emerged/evolved over time (biological progression).
BODY Task 1. Define cohorts of transcript alterations that associate with high grade (Gleason pattern 4-5) versus low grade (Gleason pattern 3) cancers
A number of studies have reported gene expression signatures correlating with Gleason grade using expression arrays 3-8 .
To date however, consensus among Gleason Pattern (GP)-associated transcriptional profiles in localized prostate cancer has not been determined, in part because technology at that time did not facilitate genome wide analyses. The heterogeneity of the prostate samples assessed on each study (various representations of tumor cells and ratios of tumor cells-to normal glands-and-stroma, versus microdissected samples highly enriched with tumor cells) may also contribute to the lack of consistency among studies.
Using older, partial-genome microarrays (PEDB cDNA microarray, 3708-unique-genes) and LCM samples, our group has previously identified a 86-gene classifier capable of distinguishing low-grade (Gleason Pattern 3: GP3) from high-grade (Gleason Pattern 4 & 5: GP4 and GP5, respectively) cancers 7 . To expand our analysis, and create a more comprehensive GP-associated gene panel, I undertook an additional independent discovery effort to define GP-associated transcripts using contemporary full-genome expression arrays (Agilent 44K oligonucleotide microarray, 19643-unique-genes) and profiled transcripts across a separate set of microdissected prostatic tissue (Figure1).
Twenty five samples were from non-neoplastic prostate epithelium adjacent to tumor, referred herein as benign samples.
The tumor samples included GP3 cells (n=15) from: 9 GS (3+3) cases, 4 GS(3+4) and 1 GS(4+3) cases, and GP4 cells (n=13) from: 4 GS(3+4) cases, 3 GS(4+3) cases, and 6 GS(4+4) cases. These Gleason grades correspond to the scores assigned to the tissue blocks from which the cells were microdissected and in some cases differed from the Clinical
Gleason score assigned to the radical prostatectomy tissue (RP-Gleason). Patient demographic characteristics are show in Table 1 . Of the 25 cases, I excluded one case due to poor microarray hybridization. Pathological review of the LCM images verified the intended GP3 and GP4 cells collected, respectively.
For the Agilent microarray experiment, probe labeling and hybridization was performed following the manufacturer's suggested protocols and fluorescent array images were collected using the Agilent DNA microarray scanner G2565BA.
Data was loess normalized within arrays and quantile normalized between arrays in R using the Limma Bioconductor package. Our new Agilent microarray data consisted of two-channel ratios of the benign, GP3 and GP4 microdissected prostate tissue, all hybridized against a common reference sample.
Unsupervised cluster analysis using the top 1000 most variable genes, clearly grouped the samples into two branches:
branch I represented by benign samples and branch II represented by cancer samples, regardless of Gleason grade ( Figure   2A ). As expected, prostate cancer associated transcripts, such as AMACR and HPN, were significantly up regulated in cancer compared to benign samples ( Figure 2B ). This result confirms, at the molecular level, that an accurate microdissection of the intended cell type was achieved.
To explore the relationship between GP3 and GP4 samples, we performed Principal Component Analysis (PCA) for all the genes in the arrays ( Figure 2C ). PCA clearly grouped a subset of genes that discriminated benign and cancer samples, confirming that the major differences resulted from the differential expression of large numbers of genes between the benign and cancer samples and not by Gleason grade, as observed in the dendogram described above. Nevertheless, within the Gleason samples, PCA could partially separate GP3 from GP4 samples as shown in Figure 2C (arrowheads).
To further characterize the relationships between GP3 and GP4 samples, the interquartile range of virtual head-to-head ratios of each cancer sample (to the patient-matched normal) was computed and the top 1000 most variable genes were clustered using Pearson correlation distance and average linkage (Figure 3 ). Cancer samples were grouped into 4 major branches: Branch I is represented by GP3 samples microdissected from RP-Gleason 3+4 and no biochemical recurrence (BRC), branch II and III represented by GP4 samples from RP-Gleason 4+4 with biochemical recurrence and metastatic outcomes, and branch IV and V represented by an intermediate group of GP3 and GP4 with RP-Gleason 3+4 and 4+3 samples and some recurrence cases. These observations suggest that a molecular signature can distinguish low-grade, low risk PCa (branch I) from the most aggressive high-grade, high risk PCa (branches II and III). However, the histological defined Gleason specific transcripts do not represent a dichotomous variant, and that the expression is rather a continuum from less aggressive to more aggressive cancers as represented by branch IV.
To identify genes whose expression in GP4 significantly differed from GP3 samples we used the Statistical Analysis of Microarray (SAM) program 9 and applied an unpaired, two-sample t-tests analysis and controlled for multiple testing by estimation of q-values using the false discovery rate (FDR) method. This analysis defined a cohort of 620 mRNAs with GP-associated differential expression (Figure 4 ). For the identification of candidate-urine-biomarkers, I focused on transcripts highly expressed in GP4 rather than down-regulated in GP4. We believe this approach (Up in GP4) will facilitate the quantitative analysis in urine samples, since a low or lack of expression of a gene does not rule out low representation of prostate cancer cells in urine, or a unsuccessful qPCR reaction. Still, the inclusion of few (one, or two)
down-regulated genes in GP4 among several up-regulated genes could also be valuable when considering a gene-panel.
Among the significantly differentially expressed genes, RGS5 was the most upregulated gene with a 15 fold-enrichment in GP4 compared to GP3 and Normal (Table 2) . Further, within the significantly up-regulated gene list, I have found that several GP-associated transcripts, such as RGS5 RELN and C5orf30 or a combination of them associate with adverse clinical outcomes, such as biochemical recurrence following primary therapy, as expected based on the known adverse outcomes associated with higher Gleason scores 10 ( Figure 5 ).
In order to compare our new full-genome expression array with our partial genome array, we merged the Agilent and PEDB Gleason datasets. After spot quality assessment, the merged data contained 3011 unique genes in common between both platforms. The True et al. PEDB microarray data consisted of two-channel head-to-head ratios of lasercapture microdissected Gleason 3, 4, and 5 patterns of cancer against patient-matched benign epithelium. Using these ratios we compared GP3 with either GP4 alone or GP4 combined with GP5. Our new Agilent microarray data consisted of two-channel ratios of laser-capture microdissected epithelium and GP3 and GP4 cancer cells, all hybridized against a common reference sample. A low but significant correlation coefficient of 0.23 (p<0.0001) between the two distinct microarray experiments was determined using the scored T-test.
Initially we compared the original ratios for each platform to identify common differentially expressed genes between GP3 and GP4. Additionally, we created virtual head-to-head ratios of each cancer sample compared to the patientmatched normal and compared the groups again. Overlap of genes with q-values less than 10% were computed and shown by Venn diagrams ( Figure 6 ). Seventy genes were significantly up-regulated in both studies and only 6 genes down-regulated ( Fig 6A and 6B ) using the original ratios calculated for each platform. MAOA, whose higher expression was previously confirmed at the protein level, was among the genes in common between both platforms. Other genes significantly up-regulated in high Gleason in the PEDB data set, such as DAD1, were not up-regulated in GP4 in our new Agilent array. Using the virtual head-to head-ratios to create the Venn Diagrams, the overlap between both studies was significantly reduced to only 13 genes up-regulated and 3 down-regulated in GP4 compared to GP3. ( Figure 6C ). This low overlap, besides being affected by the different platforms used and the low number of common genes (3011 genes),
suggest that a GP-associated signature is not a robust phenotype, even though histological defined Gleason patter cells were laser captured microdissected in both studies.
In order to generate a comprehensive GP-associated gene candidate list, we integrated our two array datasets described above, with the meta-analysis-determined grade-associated transcripts and selected those mRNAs consistently upregulated in GP4 PC relative to benign epithelium and GP3 PC ( Table 2 ). The meta-analysis consisted of a cross-study normalized matrix of mRNA expression comprising data from 251 benign prostate tissue samples, 852 primary prostate cancers samples, and 47 metastatic samples. With this matrix, we created a gene list of transcripts differentially expressed between GS6 and GS8-9. The GP-associated candidates were generated based on: i) most significant difference between low-and high-grade cancer in Agilent dataset; ii) highest overexpression in GP4 iii) previously validated; vi) overlap with PEDB dataset and meta-analysis; and v) Preferentially express in prostate tissue compared to bladder and kidney tissues were also analyzed by qPCR. Twenty-five of thirty-three genes tested confirmed the microarray results. Representative results for the qPCR analyses are shown in Figure 7 and p-values for all the genes testes are in Table 2 . To validate the differential expression in an independent cohort, aliquots of the same samples that were amplified and labeled to generate the original PEDB expression profile were used for qPCR analyses (Cohort 1, C1.). Eleven of the Twenty-three genes tested to date, were significantly up-regulated in GP4/GP5 compared to benign and GP3 PC, validating the results obtained in cohort 2 (C2) ( Table 2) . Representative results for 4 markers are shown in Figure 8C . I will evaluate the expression of candidate genes in a second independent cohort consisting of RNAs extracted from 20 frozen section containing >70% cancer with Gleason 3+3 (n=20) and twenty of Gleason 4+4, respectively.
Validation of a Gleason pattern associated transcript panel in urine sediments
. I have also begun the development of qPCR for the quantitative determination of transcript levels in urine from patients presenting for needle biopsy. As an initial experiment in urine samples, we tested 5 candidate genes in a small cohort of urine sediments from biopsy cases.
Within this cohort, n=5 cases were GS6; n=5 GS ≥8 and n=5 had negative biopsy. The transcript levels for these 5 genes were readably detectable in the urine sediment by qPCR, demonstrating the feasibility of our assay using SYBG qPCR.
The cycle number for PSA ranged between 27-32 Ct. In order to confirm the presence of prostate cells in urine and normalize the cycle number obtained by qPCR, we used the prostate specific marker: PSA (KLK3). Different studies have reported several normalization strategies in which, only PSA is used to normalize the Ct, or a house keeping gene (e.g. GAPDH) is used to normalize for total RNA in combination with PSA which will internally normalize for prostate cells (Ct PSA + Ct GAPDH )/2 -Ct Variable ). After employing these two normalization strategies, none of the candidate genes tested were statistically significantly up-regulated in bx GS≥8, compared to either NEG or GS6 (see Table 3 for p-values for each gene tested and Figure 8 for representative results). Nevertheless, the box plots in Figure 8E demonstrate a trend for higher expression of the candidate genes in GS≥8. When an unpaired t-test analysis is performed between negative versus positive biopsy, the expression of HOXD3 and WNK3 were significantly up-regulated in positive biopsy samples, regardless of its Gleason score.
The lack of significant alterations of the candidate genes between NEG, GS6 and GS≥8 from urine sediments could have been influenced by multiple reasons: 1) High variability in expression levels between samples, as shown in Figure 8A to 8D the GP4 samples have a wide range of expression per case (red points), thus with o low number of samples significance cannot be reached; 2) Very low volumes of high-grade cancer that may not release quantities of cells and resultant transcripts sufficient for detection 3) Expression of genes in urothelial cells; 4) The use of a single prostate specific marker PSA, which is highly variable among samples (Ct range 27-32) could affect the final normalized results, since the normalized Ct are highly influenced by the PSA concentration, I suggest including few more prostate specific transcripts that could be used for normalization. In order to identify those candidates, I will use our gene expression data sets and identified genes that were not significantly altered between benign and GP3 ad GP4 such and that are not expressed in bladder, kidney and immune cells.
Another imperative aspect when developing the urine assay is to use the most appropriate samples to develop the assay and create a model. The low certainty on the accuracy between the biopsy and clinical Gleason scores, underscores the need of using urine sediments from radical prostatectomy cases (from which the clinical Gleason score is assigned) in order to develop an accurate model of urine biomarkers for high grade prostate cancer detection.
Since GP-associated transcript levels represent a continuum of expression with higher levels correlating with high
Gleason grade, and that do not behave as a dichotomous variable, a multivariate logistic regression analysis might prove to be valuable to define significance among several genes. Thus, we expect that a panel of grade-associated markers will be required.
If we do not find correlation between the GP markers and significant cancers on biopsy or prostatectomy, we will combine data from the Gleason marker assays with urinary TMPRSS2:ERG and PCA3 data 11 and establish multivariate models that may perform better at distinguishing apparently indolent disease.
KEY RESEARCH ACCOMPLISHMENTS:
 I have identified a 46-gene expression profile that correlates with high Gleason grade prostate cancer (Task 1)  25/33 genes tested by qPCR confirmed the Agilent microarray results from prostatectomy tissue specimens (Task 2)  11/23 genes tested by qPCR to date, validated the GP-associated expression using an independent prostatectomy tissue specimens cohort (Task 2)  A subset of the 46-gene candidates identified associate with prostate cancer recurrence (Task 2)  Established an RNA-based urine assay by qPCR using urine sediments from biopsies (Task 2) REPORTABLE OUTCOMES: I have identified a molecular signature that underlies the histological classification of prostate cancer Gleason grades using both, gene expression analyses and cross-comparison between publically available datasets. I have identified gene outliers within the GP4 group, that could have the potential to discriminate low versus high Gleason grade when use as a gene-panel. Further, I have found that several GP-associated transcripts correlate with adverse clinical outcomes.
Although, cluster analysis revealed that a molecular signature can distinguish low-grade, low risk PCa from the most aggressive high-grade, high risk PCa, --the GP-expression phenotype is not a robust, nor a dichotomous variant, and that gene expression levels are rather a continuum from less aggressive to more aggressive cancers. Thus, taken together, this data confirms the concept of implementing a biomarker-panel rather than a single biomarker for the assessment of nonindolent PCa in urine.
In order to test GP-associated candidate genes in urine samples, it is essential to perform the assays using urine collected from patients undergoing radical prostatectomies, rather than biopsy, in order to be confident of the Gleason score assigned and thus incorporate that information into the model.
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(G4/N vs. G3/N) RGS5* 0 14.3 n/a n/a 0.001 0.009 0.150 YES n/a GRIN3A 0 6.8 n/a n/a 0.001 0.842 0.910 no 1.4 FRY 0 5.8 n/a n/a 0.000 0.105 0.256 no 1.1 IL1RAPL1 0 5.7 1 1.3 0.013 0.968 0.601 no 1.0 NRP1 0 5.5 n/a n/a n/a n/a n/a no 1.1 CXCR7* 0 5.3 14 1.3 0.000 0.002 0.079 no 1.0 SSTR1 0 5.2 n/a n/a 0.067 n/a n/a YES 1.0 HOXD3 0 5.0 n/a n/a 0.000 0.224 0.231 YES 1.0 LRRN1* 0 4.7 n/a n/a 0.000 0.035 0.089 no 1.6 RFX6 1 4.4 n/a n/a 0.039 n/a n/a YES 1.2 FCGR3A 0 4.1 10 2.0 n/a n/a n/a no 1.1 GRIK1 4 4.1 6 1.4 n/a n/a n/a YES -1.0 C5orf30* 0 3.8 n/a n/a 0.001 0.048 0.075 YES 1.1 MCTP1 0 3.8 n/a n/a 0.002 n/a n/a no 1.0 MID1 0 3.8 n/a n/a 0.144 n/a n/a no 1.0 PECAM1 0 3.3 n/a n/a n/a n/a n/a no 1.1 ONECUT2 1 3.2 n/a n/a 0.085 n/a n/a YES 1.0 HEG1* 0 3.2 n/a n/a 0.000 0.044 0.143 no -1.0 CXCL12 2 3.2 48 1.1 n/a n/a n/a no -1.1 WFDC5 11 2.9 n/a n/a 0.186 n/a n/a YES -1.1 HIGD1B 0 2.8 n/a n/a n/a n/a n/a no -1.0 C11orf80 0 2.8 n/a n/a 0.001 n/a n/a no 1.1 RELN 7 2.8 n/a n/a 0.066 n/a n/a YES 1.1 UTS2D 2 2.7 n/a n/a 0.005 n/a n/a YES 1.0 ZMIZ1* 0 2.7 n/a n/a 0.000 0.015 0.041 no 1.1 CILP 3 2.6 n/a n/a n/a n/a n/a YES -1.0 PDZD2 0 2.5 n/a n/a 0.004 0.145 0.355 no 1.0 WNK3* 0 2.5 n/a n/a 0.004 0.004 0.011 no 1.2 RAB23* 0 2.5 n/a n/a 0.001 0.002 0.035 no -1.0 KCTD12* 0 2.3 3 2.1 0.000 0.001 0.038 no 1.1 IMPA1 1 2.3 9 1.4 n/a n/a n/a no 1.1 CDON 0 2.3 n/a n/a n/a n/a n/a no 1.0 BICC1 0 2.2 n/a n/a 0.100 0. n/a n/a no 1.1 ZNF492 14 -1.0 n/a n/a n/a n/a n/a no -1.0 CLEC14A 45 -1.1 n/a n/a 0.003 n/a n/a YES 1.1 PSGR2 n/a n/a n/a n/a n/a n/a n/a n/a 1.5 *Genes validated by qPCR ; n/a: not present, not measured ** Prognostic value as determined using Taylor et al 10 data set in the cBioPortal for Cancer Genomics site Selection of a 46-Gene Panel B G3 G4 B G3 G4 B G3 G4 Figure 7 . Confirmation of GP-associated transcripts. qPCR assays were developed to confirm GPassociated transcripts. Shown are 15 representative genes. Each data point represents an independent PC sample. * is p<0.05 for the indicated comparison.
